MeiraGTx Holdings PLC (MGTX)

NASDAQ
Currency in USD
7.87
+0.08(+1.03%)
Closed
After Hours
8.05+0.18(+2.29%)
MGTX Scorecard
Full Analysis
Quickly burning through cash
Fair Value
Day's Range
7.668.07
52 wk Range
3.858.75
Key Statistics
Edit
Prev. Close
7.79
Open
7.93
Day's Range
7.66-8.07
52 wk Range
3.85-8.75
Volume
559.14K
Average Volume (3m)
446.6K
1-Year Change
22.68%
Book Value / Share
0.87
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MGTX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
23.20
Upside
+194.79%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week
Show more

MeiraGTx Holdings PLC Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and a strategic collaboration with Hologen Limited to develop Phase 3 clinical trials for AAV-GAD to treat Parkinson’s disease. The company was incorporated in 2015 and is based in New York, New York.

MeiraGTx Holdings PLC SWOT Analysis


Gene Therapy Pionee
MeiraGTx's diverse pipeline spans treatments for xerostomia, X-linked retinitis pigmentosa, and Parkinson's disease, positioning it as a leader in gene therapy innovation
Financial Fortification
Explore how MeiraGTx secured $50 million in equity financing, including a significant $30 million investment from pharmaceutical giant Sanofi, bolstering its research capabilities
Regulatory Milestones
Learn about MeiraGTx's crucial FDA alignment for its xerostomia treatment, potentially supporting a Biologics License Application by 2026 and accelerating market entry
Market Valuation
Analyst price targets range from $11 to $36, suggesting significant upside potential despite the stock's current "Speculative Risk" qualifier and recent price target adjustment
Read full SWOT analysis

Compare MGTX to Peers and Sector

Metrics to compare
MGTX
Peers
Sector
Relationship
P/E Ratio
−4.2x−1.0x−0.5x
PEG Ratio
0.10−0.010.00
Price/Book
9.1x1.0x2.6x
Price / LTM Sales
18.6x8.8x3.0x
Upside (Analyst Target)
220.9%547.1%56.4%
Fair Value Upside
Unlock23.9%9.9%Unlock

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.20
(+194.79% Upside)

Earnings

Latest Release
Mar 13, 2025
EPS / Forecast
-0.49 / -0.57
Revenue / Forecast
21.39M / 1.20M
EPS Revisions
Last 90 days

FAQ

What Is the MeiraGTx (MGTX) Stock Price Today?

The MeiraGTx stock price today is 7.87

What Stock Exchange Does MeiraGTx Trade On?

MeiraGTx is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for MeiraGTx?

The stock symbol for MeiraGTx is "MGTX."

What Is the MeiraGTx Market Cap?

As of today, MeiraGTx market cap is 617.43M.

What is MeiraGTx Earnings Per Share?

The MeiraGTx EPS is -2.12.

What Is the Next MeiraGTx Earnings Date?

MeiraGTx will release its next earnings report on 07 May 2025.

From a Technical Analysis Perspective, Is MGTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.